Zhang Xue-Fang, Zhang Shu-Ying, Zhou Hong, Feng Jia-Wei, Jiang Li-Bo, Qu Yan-Zhang, Guo Heng, Wang Shu-Liang
Department of Hematology, The Second Affiliated Hospital of Qiqihar Medical College, Qiqihar 161006, Heilongjiang Province, China.
Department of Hematology, The Second Affiliated Hospital of Qiqihar Medical College, Qiqihar 161006, Heilongjiang Province, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Feb;26(1):208-212. doi: 10.7534/j.issn.1009-2137.2018.01.036.
To explore the relationship between expression of CD96 and CD123 and prognosis of patients with myelodysplastic syndrome(MDS).
Eight-nine MDS patients(MDS group) and 20 persons without hematologic disease as controls(Control group) were enrolled. The patients were grouped by the risk. All participants received bone marrow biopsy. Mononuclear cells were extracted, CD34CD38CD123 and CD34CD38CD96 cells were counted by using flow cytometry. Expressions of 2 type cells in control group, MDS group and its subgroups were analyzed.
The proportion of CD34 cells and CD34CD38 cells in mononuclear cells of patients in MDS group was higher than in control group (P<0.05). The proportions of CD34CD38CD123 cells and CD34CD38CD96 cells in CD34CD38 cells were significantly higher than that in control group(P<0.05) and the proportion increased with the risk. In the low-and middle-risk group, the rates of complete remission(CR) and partial remission(PR) of patients with CD123 and CD96 were higher than those in patients with CD123 and CD96; in the middle-2 and high risk patients, the PR of patients with CD123 was higher than that in patients with CD123(P<0.05). The CR rate of patients with CD96 was higher than that of patients with CD96(P<0.05).
The differentiation of CD34 cells in bone marrow of MDS patients is abnormal, and the high expression of CD123 and CD96 cells existes. These findings may partially explain the cause of hematopoietic stem cell malignant clone in MDS patients.
探讨CD96和CD123表达与骨髓增生异常综合征（MDS）患者预后的关系。
纳入89例MDS患者（MDS组）和20例无血液系统疾病者作为对照（对照组）。患者按危险度分组。所有参与者均接受骨髓活检。提取单个核细胞，采用流式细胞术计数CD34⁺CD38⁻CD123⁺和CD34⁺CD38⁻CD96⁺细胞。分析对照组、MDS组及其亚组中2种类型细胞的表达情况。
MDS组患者单个核细胞中CD34⁺细胞和CD34⁺CD38⁻细胞比例高于对照组（P<0.05）。CD34⁺CD38⁻细胞中CD34⁺CD38⁻CD123⁺细胞和CD34⁺CD38⁻CD96⁺细胞比例显著高于对照组（P<0.05），且比例随危险度增加。在低、中危组中，CD123⁻和CD96⁻患者的完全缓解（CR）率和部分缓解（PR）率高于CD123⁺和CD96⁺患者；在中2和高危患者中，CD123⁺患者的PR率高于CD123⁻患者（P<0.05）。CD96⁻患者的CR率高于CD96⁺患者（P<0.05）。
MDS患者骨髓中CD34⁺细胞分化异常，存在CD123⁺和CD96⁺细胞高表达。这些发现可能部分解释MDS患者造血干细胞恶性克隆的原因。
